Inotiv, Inc. (NOTV)
| Market Cap | 9.91M |
| Revenue (ttm) | 514.03M |
| Net Income (ttm) | -69.37M |
| Shares Out | 34.39M |
| EPS (ttm) | -2.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 384,607 |
| Open | 0.303 |
| Previous Close | 0.291 |
| Day's Range | 0.286 - 0.310 |
| 52-Week Range | 0.216 - 3.320 |
| Beta | 4.08 |
| Analysts | Strong Buy |
| Price Target | 1.50 (+420.65%) |
| Earnings Date | May 11, 2026 |
About NOTV
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the ... [Read more]
Financial Performance
In fiscal year 2025, Inotiv's revenue was $513.02 million, an increase of 4.54% compared to the previous year's $490.74 million. Losses were -$68.63 million, -36.72% less than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for NOTV stock is "Strong Buy" and the 12-month stock price target is $1.5.
News
Inotiv Provides Notice Regarding Cybersecurity Incident
WEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dr...
Inotiv Earnings Call Transcript: Q1 2026
Q1 2026 delivered strong DSA growth and margin improvement, offset by RMS weakness from lower NHP volumes. Cost reduction and site optimization efforts are underway, with innovation and new collaborations supporting future growth. No formal FY 2026 guidance was provided.
Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update
WEST LAFAYETTE, Ind., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery ...
Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026
WEST LAFAYETTE, Ind., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dr...
Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery
WEST LAFAYETTE, Ind., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical dr...
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities
WEST LAFAYETTE, Ind., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization (CRO) specializing in nonclinical and analyti...
Inotiv Earnings Call Transcript: Q4 2025
Q4 and FY25 saw robust revenue and margin growth, led by DSA, despite a cybersecurity incident. RMS site consolidation and IT streamlining drove cost savings, while legal settlements and refinancing efforts improved the balance sheet. DSA demand and awards remain strong.
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update
– Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million– Fiscal 2025 revenue increased 4.5% to $513.0 million– Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million– Fis...
Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™
Building a Unified, Client-Focused, Early Stage CRO Through Strategic Expansion and Service Development Powers 448% Revenue Growth from Fiscal Year 2021 to Fiscal Year 2024 Building a Unified, Client-...
Inotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025
WEST LAFAYETTE, Ind., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dr...
Inotiv Transcript: Jefferies London Healthcare Conference 2025
Q4 saw strong revenue and DSA award growth, with operational efficiencies from integration and site consolidation. Pricing has firmed, margins are improving, and NHP activity stabilized. Debt restructuring and cyber recovery efforts are ongoing, with systems fully restored.
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results
Preliminary Expected Fourth Quarter 2025 Revenue of $137.5 to $138.5 Million Preliminary Expected Full Year 2025 Revenue of $512.5 to $513.5 Million
Halper Sadeh LLC Encourages Inotiv, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Inotiv, Inc. (NASDAQ: NOTV) breached their fiduciary duties to shar...
Inotiv Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Significant growth achieved through integration, operational optimization, and a focus on preclinical CRO services. Recent quarters saw strong DSA award growth and improved financial performance, with a clear path to long-term EBITDA targets. Customer-centric strategies and infrastructure investments underpin future expansion.
Inotiv Transcript: Baird Global Healthcare Conference 2025
Integration of acquisitions and operational streamlining have stabilized the RMS business and driven strong growth in DSA, with high incremental margins and improved conversion rates. Market growth remains flat, with gains attributed to internal improvements and targeted investments. Regulatory and funding challenges are being managed, and capacity is sufficient for near-term growth.
Inotiv, Inc. to Participate in Three Investor Conferences in September 2025
WEST LAFAYETTE, Ind., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dr...
CORRECTING and REPLACING - Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update
In a release issued under the same headline on August 6, 2025 by Inotiv, Inc. (NASDAQ: NOTV), please note that the amount of the recent draw request on the revolving credit facility has been corrected...
Inotiv Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 23.5% year-over-year to $130.7M, with improved margins and narrowed net loss. DSA and RMS segments both saw strong growth, while management remains cautious amid elevated cancellations and macroeconomic risks.
Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update
– Third quarter fiscal 2025 revenue up 23.5% to $130.7 million– Year-to-date fiscal 2025 revenue increased 4.0% to $374.9 million– Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind...
Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and Host Conference Call on Wednesday, August 6, 2025
WEST LAFAYETTE, Ind., July 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dr...
Inotiv Transcript: Jefferies Global Healthcare Conference 2025
Bookings and margins are improving, led by Discovery and better client retention. RMS margins have rebounded, and NHP supply is stable but limited. Revenue and EBITDA growth depend on sustained momentum, while proactive lender engagement and balance sheet improvements are top near-term priorities.
Inotiv, Inc. to Present at Jefferies Global Healthcare Conference 2025
WEST LAFAYETTE, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug...
Inotiv Earnings Call Transcript: Q2 2025
Q2 FY2025 revenue rose 4.4% year-over-year to $124.3M, led by RMS growth from higher NHP sales, while DSA margins declined but quoting and awards activity was strong. Adjusted EBITDA improved to $8M, and a revised RMS optimization plan is expected to deliver higher savings sooner.
Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update
— Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million— Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million— Conference call scheduled for today at 4:30 pm ET WEST LAFAY...